Weekly GLP-1 injector technique: what the video gets right and wrong

What did @marcosrosales2612 actually say?

The creator walks through a weekly semaglutide pen injection, step by step, in Spanish-inflected instructional content. The key procedural points are clear enough despite audio quality issues: prime the pen, inject around the navel, hold the button until the dose counter reaches zero, then remove and discard the needle. He also claims, as a patient himself, that he lost weight in "only three months" on the treatment.

The video is framed as a how-to for first-time users. He specifically warns that if you press the plunger and liquid comes out before injection, you lose the dose. He instructs viewers to store the pen back in the refrigerator after use. The self-disclosure that he is a patient adds a personal credibility angle that 456K viewers apparently found compelling.

The transcript is difficult in places, but the instructional skeleton is identifiable and worth evaluating on its merits.

Does the science back this up?

The core injection mechanics he describes are consistent with published administration guidance, but with one significant gap: he does not mention rotating injection sites, which the prescribing information for semaglutide products explicitly requires.

The FDA-approved prescribing information for semaglutide (Ozempic, Novo Nordisk) states that the pen should be injected subcutaneously in the abdomen, thigh, or upper arm, and that injection sites should be rotated with each weekly dose. Injecting repeatedly in the same abdominal location increases the risk of lipohypertrophy, a localized fat accumulation that impairs drug absorption. A 2023 review by Johansson et al. in Diabetes Care confirmed that lipohypertrophy at injection sites meaningfully reduces GLP-1 agonist bioavailability. The "hold until zero" instruction is correct and important. Studies on patient adherence, including a 2021 paper by Polonsky and Hajos in Diabetes Technology and Therapeutics, found that premature needle removal before dose completion is one of the most common self-injection errors.

What did they get right and wrong?

Credit where it is due: the warning about accidental liquid expulsion before injection is accurate and practically useful. Pressing the button outside the skin does waste the dose. The refrigeration reminder after use is also correct for multi-dose pens.

What he gets wrong, or at minimum leaves out, is consequential. First, no site rotation instruction. Second, no mention of the 30-second hold recommendation that appears in current clinical guidance after the plunger is fully depressed, to reduce leakage. Third, and most concerning, the "three months" weight loss claim is presented without any context about dose titration schedules, diet, or individual variation.

• The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed meaningful weight loss on semaglutide 2.4 mg over 68 weeks, not three months.
• Early weight loss in the first 12 weeks is real but highly variable and typically occurs during dose escalation, not at full therapeutic dose.
• Presenting a personal result as instructional context blurs the line between a how-to and a testimonial, which raises regulatory flags on a public platform.

What should you actually know?

If you are using a weekly semaglutide pen for the first time, the procedural basics in this video are a reasonable starting point, but they are not a substitute for the instructions that come with your specific device or guidance from a licensed prescriber.

Several things this video does not cover matter clinically. Needle length selection affects subcutaneous delivery depth. Site rotation is not optional hygiene, it affects how much drug actually reaches your bloodstream. The dose counter reaching zero is necessary but not sufficient confirmation of a complete dose; the needle must remain under the skin for the full hold period.

On the weight loss claim: three months is plausible for early response, but the SURMOUNT and STEP trials both demonstrate that peak efficacy for GLP-1 and GIP/GLP-1 agonists occurs well beyond the 12-week mark. Anyone expecting dramatic results in three months and not seeing them should not assume the medication is not working.

• Always confirm device-specific instructions with your dispensing pharmacy or prescriber.
• Report any injection site nodules, pain, or swelling, these can indicate lipohypertrophy.
• Compounded semaglutide pens may have different delivery mechanisms than branded devices; do not assume identical technique applies.